(Q36496844)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752165%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

review article

1 reference

title

Antipsychotic drugs and diabetes--an application of the Austin Bradford Hill criteria (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752165%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752165%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

R C Peveler

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752165%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

1 reference

13 May 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752165%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752165%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752165%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752165%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

1467-1476

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16752165%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00125-006-0279-3

29 January 2020

exact match

0 references

cites work

Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00125-006-0279-3

Incident Diabetes Associated With Antipsychotic Use in the United Kingdom General Practice Research Debate

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00125-006-0279-3

Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among Central Texas veterans

21 January 2018

1 reference

12 December 2020

Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications

1 reference

12 December 2020

Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients

1 reference

12 December 2020

Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders

1 reference

12 December 2020

Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs

1 reference

12 December 2020

Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus

1 reference

12 December 2020

The association of weight gain and olanzapine plasma concentrations.

1 reference

12 December 2020

Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study

1 reference

12 December 2020

Glucose tolerance and serum insulin levels in an animal model of obesity induced by sub-acute or chronic administration of antipsychotic drugs

1 reference

12 December 2020

Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells.

1 reference

12 December 2020

A study on the types of diabetes mellitus in first degree relatives of diabetic patients

1 reference

12 December 2020

Family history of type 2 diabetes in schizophrenic patients

1 reference

12 December 2020

Dosing of Second-Generation Antipsychotic Medication in a State Hospital System

1 reference

12 December 2020

Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders

1 reference

12 December 2020

Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population

1 reference

12 December 2020

Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine

1 reference

12 December 2020

Principles of epidemiological research on adverse and beneficial drug effects.

1 reference

12 December 2020

Antipsychotics and diabetes: review of non-prospective data.

1 reference

12 December 2020

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

1 reference

12 December 2020

Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults

1 reference

12 December 2020

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study

1 reference

12 December 2020

Clozapine use and risk of diabetes mellitus

1 reference

12 December 2020

Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine

1 reference

12 December 2020

Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs

1 reference

12 December 2020

1 reference

12 December 2020

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

1 reference

12 December 2020

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

1 reference

12 December 2020

Association between antipsychotic drugs and diabetes

1 reference

12 December 2020

Testing for diabetes in hospitalised patients prescribed antipsychotic drugs

1 reference

12 December 2020

The unhealthy lifestyle of people with schizophrenia

1 reference

12 December 2020

Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia

1 reference

12 December 2020

A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia

1 reference

12 December 2020

Diabetes and schizophrenia 2005: are we any closer to understanding the link?

1 reference

12 December 2020

The Environment and Disease: Association or Causation?

1 reference

12 December 2020

The atypical antipsychotics quetiapine, risperidone and ziprasidone do not increase insulin release in vitro.

1 reference

12 December 2020

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

1 reference

12 December 2020

Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria

1 reference

12 December 2020

The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.

1 reference

12 December 2020

Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases

1 reference

12 December 2020

Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp

1 reference

12 December 2020

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

1 reference

12 December 2020

The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link?

1 reference

12 December 2020

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

1 reference

12 December 2020

Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia

1 reference

12 December 2020

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

1 reference

12 December 2020

The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents.

1 reference

12 December 2020

Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia

1 reference

12 December 2020

Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims

1 reference

12 December 2020

A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States

1 reference

12 December 2020

Antipsychotic-induced type 2 diabetes: evidence from a large health plan database

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia

1 reference

12 December 2020

Weight change with atypical antipsychotics in the treatment of schizophrenia

1 reference

12 December 2020

Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program

1 reference

12 December 2020

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.

1 reference

12 December 2020

Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients

1 reference

12 December 2020

Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database

1 reference

12 December 2020

Quetiapine in the successful treatment of psychosis and comorbid brittle diabetes mellitus: a case report

1 reference

12 December 2020

Euglycemic clamp study in clozapine-induced diabetic ketoacidosis

1 reference

12 December 2020

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

1 reference

12 December 2020

The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England

1 reference

12 December 2020

Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials

1 reference

12 December 2020

Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study

1 reference

12 December 2020

Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia

1 reference

12 December 2020

Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial

1 reference

12 December 2020

Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach

1 reference

12 December 2020

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

1 reference

12 December 2020